march 2020 • Médecine et Maladies

No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection

Jean Michel Molina, ConstanceDelaugerre, Jerome Le Goff, Breno Mela-Lima, Diane Ponscarme Lauriane Goldwirt, Nathalie de Castro

DOI: 10.1016/j.medmal.2020.03.006

Key message

Apesar da acção anti-viral in vitro da cloroquina na COVID-19, não foi encontrada evidência de benefício na utilização da combinação hidroxicloroquina/azitromicina em doentes com COVID-19 grave. Estão a decorrer estudos randomizados que irão fornecer dados definitivos sobre eficácia e segurança desta combinação.

Abstract

In summary, despite a reported antiviral activity of chloroquine against COVID-19 in vitro, we found no evidence of a strong antiviral activity or clinical benefit of the combination of hydroxychloroquine and azithromycin for the treatment of our hospitalized patients with severe COVID-19. Ongoing randomized clinical trials with hydroxychloroquine should provide a definitive answer regarding the alleged efficacy of this combination and will assess its safety.